<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10604733</article-id><article-id pub-id-type="pmc">2362962</article-id><article-id pub-id-type="pii">6690457</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690457</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Prospective, double-blind, placebo-controlled randomized trial of cimetidine in gastric cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Langman</surname><given-names>M J S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Dunn</surname><given-names>J A</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Whiting</surname><given-names>J L</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Burton</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Hallissey</surname><given-names>M T</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fielding</surname><given-names>J W L</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kerr</surname><given-names>D J</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine and<label>2</label>Clinical Trials Unit, CRC Institute for Cancer Studies, Clinical Research Block, The Medical School, Birmingham, Edgbaston B15 2TA, UK</aff><aff id="aff3"><label>3</label>Department of Surgery, Queen Elizabeth Hospital, Birmingham B15 2TH, UK</aff><pub-date pub-type="ppub"><month>12</month><year>1999</year></pub-date><volume>81</volume><issue>8</issue><fpage>1356</fpage><lpage>1362</lpage><history><date date-type="received"><day>28</day><month>04</month><year>1999</year></date><date date-type="accepted"><day>08</day><month>07</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Cimetidine is thought to inhibit suppressor T-lymphocyte function and preliminary evidence from a randomized trial indicated that it might prolong survival for patients with operable and inoperable gastric cancer. The British Stomach Cancer Group conducted a randomized, double-blind, placebo-controlled trial examining the effects of cimetidine (400 mg or 800 mg twice a day) on the survival of patients with early (stages I, II and III: <italic>n</italic> = 229) and advanced (stages IVa and IVb: <italic>n</italic> = 201) gastric cancer. The primary end point was death. A total of 442 patients were randomized by 59 consultants in 39 hospitals between February 1990 and March 1995. Log-rank survival analysis was used to assess differences between the groups. Three hundred and forty patients died during the study: 166 (49&#x00025;) in the cimetidine treatment groups and 174 (51&#x00025;) in the placebo groups. Median survival for patients receiving cimetidine was 13 months (95&#x00025; confidence interval (CI) 9&#x02013;16 months) and 11 months in the placebo arm (95&#x00025; CI 9&#x02013;14 months). There was no significant difference in survival between the two treatment groups (<italic>P</italic> = 0.42) or between different doses of cimetidine tablets (<italic>P</italic> = 0.46). Five-year survival of those patients randomized to cimetidine was 21&#x00025; compared to 18&#x00025; for those patients randomized to placebo. Cimetidine at a dose of 400 mg or 800 mg twice a day does not have a significant influence on the survival of patients with gastric cancer compared to placebo. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>cimetidine</kwd><kwd>gastric cancer</kwd><kwd>randomized</kwd><kwd>clinical trial</kwd><kwd>H<sub>2</sub>-antagonists</kwd></kwd-group></article-meta></front></article>


